Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis

Janel O. Johnson, PhD; Ruth Chia, PhD; Danny E. Miller, MD, PhD; Rachel Li, MD; Ravindran Kumaran, PhD; Yevgeniya Abramzon, BSc; Nada Alahmady, PhD; Alan E. Renton, PhD; Simon D. Topp, PhD; J. Raphael Gibbs, PhD; Mark R. Cookson, PhD; Marya S. Sabir, BSc; Clifton L. Dalgalarrondo, PhD; Claire Troakes, PhD; Ashley R. Jones, PhD; Aleksey Shatunov, PhD; Alfredo Iacoangeli, PhD; Ahmad Al Khleifat, PhD; Nicola Ticozzi, MD, PhD; Vincenzo Silani, MD; Cinzia Gellera, PhD; Ian P. Blair, PhD; Carol Dobson-Stone, PhD; John B. Kwok, PhD; Emily S. Bonkowski, ScM; Robin Palvadeau, MSc; Pentti J. Tienari, MD; Karen E. Morrison, MD; Pamela J. Shaw, MD; Ammar Al-Chalabi, PhD; Robert H. Brown Jr, MD, PhD; Andrea Calvo, PhD; Gabriele Mora, PhD; Hind Al-Saif, MD; Marc Gotkine, MBBS; Fawn Leigh, MD; Irene J. Chang, MD; Seth J. Perlman, MD; Ian Glass, MB ChB, MD; Anna I. Scott, PhD; Christopher E. Shaw, MD; A. Nazli Basak, PhD; John E. Landers, PhD; Adrianio Chio, PhD; Thomas O. Crawford, PhD; Bradley N. Smith, PhD; Bryan J. Traynor, MD, PhD; and the FALS Sequencing Consortium; American Genome Center; International ALS Genomics Consortium; and ITALSGEN Consortium

IMPORTANCE Juvenile amyotrophic lateral sclerosis (ALS) is a rare form of ALS characterized by age of symptom onset less than 25 years and a variable presentation.

OBJECTIVE To identify the genetic variants associated with juvenile ALS.

DESIGN, SETTING, AND PARTICIPANTS In this multicenter family-based genetic study, trio whole-exome sequencing was performed to identify the disease-associated gene in a case series of unrelated patients diagnosed with juvenile ALS and severe growth retardation. The patients and their family members were enrolled at academic hospitals and a government research facility between March 1, 2016, and March 13, 2020, and were observed until October 1, 2020. Whole-exome sequencing was also performed in a series of patients with juvenile ALS. A total of 66 patients with juvenile ALS and 6258 adult patients with ALS participated in the study. Patients were selected for the study based on their diagnosis, and all eligible participants were enrolled in the study. None of the participants had a family history of neurological disorders, suggesting de novo variants as the underlying genetic mechanism.

MAIN OUTCOMES AND MEASURES De novo variants present only in the index case and not in unaffected family members.

RESULTS Trio whole-exome sequencing was performed in 3 patients diagnosed with juvenile ALS and their parents. An additional 63 patients with juvenile ALS and 6258 adult patients with ALS were subsequently screened for variants in the SPTLC1 gene. De novo variants in SPTLC1 (p.Ala20Ser in 2 patients and p.Ser331Tyr in 1 patient) were identified in 3 unrelated patients diagnosed with juvenile ALS and failure to thrive. A fourth variant (p.Leu39del) was identified in a patient with juvenile ALS where parental DNA was unavailable. Variants in this gene have been previously shown to be associated with autosomal-dominant hereditary sensory autonomic neuropathy, type 1A, by disrupting an essential enzyme complex in the sphingolipid synthesis pathway.

CONCLUSIONS AND RELEVANCE These data broaden the phenotype associated with SPTLC1 and suggest that patients presenting with juvenile ALS should be screened for variants in this gene.

Published online August 30, 2021.

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The FALS Sequencing Consortium, American Genome Center, International ALS Genomics Consortium, and ITALSGEN Consortium authors appear at the end of the article.

Corresponding Author: Bryan J. Traynor, MD, PhD, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Dr, Room 1A-213, Bethesda, MD 20892 (bryan.traynor@nih.gov).
Amyotrophic lateral sclerosis (ALS) is a relatively common neurological disorder characterized by progressive paralysis and death from respiratory failure. The vast majority of cases occur in individuals older than 40 years. In contrast, juvenile ALS (defined as an age of onset less than 25 years) is a rare form of motor neuron disease. These early-onset cases are characterized by slow progression and a variable phenotype that often makes accurate diagnosis challenging.

Considerable progress has been made in unravelling the genetic architecture underlying ALS, but much remains to be understood about this condition. Juvenile ALS is thought to be more frequently genetic in origin than the adult-onset forms, and the genetic analysis of these young-onset cases offers an opportunity to identify disease-causing genes. By extension, any gene underlying juvenile ALS may also play a role in adult-onset ALS.

De novo genetic variants may underlie at least a portion of ALS cases. Such variants would not be detected by genome-wide association studies owing to their recent occurrence and corresponding low frequency within the community. Spontaneously occurring variants are a well-known cause of neurological conditions, such as neurofibromatosis type I and Duchenne muscular dystrophy. Indeed, de novo variants of the familial ALS genes FUS, SOD1, and VCP have been described in sporadic ALS cases. Such variants are more likely to present with early-onset disorders because of their impact on fitness.

Here, we performed whole-exome sequencing of 3 patients diagnosed with juvenile ALS and their unaffected parents to identify the variants associated with their disease. None of these patients had a family history of neuromuscular disorders, suggesting de novo variations as the underlying genetic mechanism. After identifying variants in serine palmitoyltransferase, long-chain base subunit 1 (SPTLC1; OMIM, 605712) in all 3 cases, we also screened patients with juvenile ALS from Turkey for SPTLC1 variants and identified a fourth patient carrying an SPTLC1 variant.

### Methods

#### Patients

Four unrelated patients with neuromuscular symptoms consistent with juvenile ALS participated in the study between...
March 2016 and January 2021. The Table summarizes the clinical features of the 4 patients. Detailed descriptions of each patient and their recruitment are available in the eMethods in the Supplement. All participants provided written informed consent for genetic analysis according to the Declaration of Helsinki, and the Institutional Review Board of the National Institutes of Health approved the study. Members of the FALS Sequencing Consortium, American Genome Center, International ALS Genomics Consortium, and ITALSGEN Consortium can be found in the eAppendix of the Supplement.

Patient 1 presented with gradually progressive spastic diplegia and growth retardation beginning at age 5 years. By age 20 years, she had quadriplegia with marked muscle atrophy and diminished weight, brisk lower limb reflexes, tongue fasciculations and weakness, dysarthria, mild cognitive dysfunction, and respiratory failure requiring tracheostomy and ventilation. Repeated neurophysiological testing did not show evidence of sensory or autonomic dysfunction. She was diagnosed with juvenile ALS based on the revised El Escorial criteria.9

Patient 2 was a teenaged girl of African American and White race who presented with a 6-year history of gradually progressive generalized limb and bulbar weakness. She had a long-standing history of progressive weight loss of unknown cause, and her school performance began to decline in her mid-teens. Her neurological examination at presentation revealed a body mass index less than the first percentile, exaggerated lumbar lordosis, tongue fasciculations and wasting, generalized muscle atrophy and weakness, brisk asymmetric ankle reflexes, a positive Gower sign, and normal sensation (Figure 1A and B). Neurophysiological testing revealed active and chronic denervation without evidence of sensory neuropathy. Decreased sustained attention and impaired executive functioning were evident in neuropsychological evaluation. She was diagnosed with juvenile ALS based on the revised El Escorial criteria.9

Patient 3 was an 11-year-old African American girl with a history of failure to gain weight and toe walking since age 4 years. She presented at age 10 years with a deteriorating gait, hand weakness, right foot paresthesia, dysphagia, and increased sweating. Examination revealed marked atrophy, postural tachycardia, bilateral cataracts, a wasted and fasciculating tongue with an exaggerated jaw jerk, generalized fasciculations and weakness associated with hyperreflexia, and decreased pinprick sensation in a glove-and-stocking distribution (Figure 1C and D). The patient walked abnormally owing to weakness and bilateral foot drop, and she had a positive Gower sign. Neurophysiological examination showed

Figure 1. Clinical Features of Patients Diagnosed With Juvenile Amyotrophic Lateral Sclerosis

A and B, Tongue wasting and scapular winging in patient 2 carrying the p.Ala20Ser SPTLC1 variant. C and D, Tongue wasting and muscle atrophy of the lower limbs in patient 3 carrying the p.Ser331Tyr SPTLC1 variant. Note the hammertoe deformities of both feet.
sensorimotor axonal neuropathy as well as polyphasic potentials on electromyography. She was diagnosed with juvenile ALS-Plus syndrome owing to her prominent motor symptoms and modest sensory-autonomic involvement. The pedigrees of patients 1, 2, and 3 are shown in Figure 2A to C.

Patient 4 was a 34-year-old Turkish woman with a history of arm and leg weakness and atrophy since age 15 years. There was no family history of neuromuscular disease, and none of her 5 siblings had symptoms (Figure 2D). She was diagnosed with juvenile ALS, and she has been taking riluzole since age 15 years. Her symptoms were slowly progressive, and there were no upper motor neuron signs on examination. During her last review at age 34 years, she used a wheelchair, although she could walk short distances with assistance. She had no dysphagia and did not require oxygen supplementation, and her weight was normal. Neurophysiologic examination at that time revealed denervation activity in all muscles and no evidence of multifocal motor neuropathy.

For variant screening of SPTLC1 in adult-onset ALS, we used 6258 DNA samples obtained from individuals diagnosed with adult-onset ALS (eTable 1 in the Supplement). Control data consisted of 5710 neurologically healthy US individuals who had undergone next-generation sequencing at the Laboratory of Neurogenetics of the National Institute on Aging, National Institutes of Health, Bethesda, Maryland, or the Alzheimer Disease Sequencing Project.

Next-Generation Sequencing in Juvenile ALS
Whole-exome sequencing was performed using 100-base-pair, paired-end sequencing on an Illumina sequencer (eg, HiSeq 2000) according to the manufacturer’s protocol. DNA from patient 1 and her family was sequenced in the Laboratory of Neurogenetics using TruSeq library preparation version 1.0. DNA from patients 2 and 3 and their families was sequenced at GeneDx using IDT xGen Exome Research Panel version 1.0.

Data were analyzed to identify de novo variants present in the affected child and not present in either parent. As the variants underlying a rare disease, such as ALS, are unlikely to be present in the general population, variants present in the Genome Aggregation Database (gnomAD; version 2.1) or the Kaviar Genomic Variant database (September 23, 2015, version) were excluded. Synonymous, intronic, and intergenic changes were excluded (ANNOVAR; August 11, 2016, version). Paternity and maternity were confirmed using identity-by-descent analysis, and exome data were reviewed to identify variants in known ALS genes.

SPTLC1 Sequencing in Adult-Onset ALS
DNA from 6258 patients with adult-onset ALS were sequenced to identify variants in the SPTLC1 gene (whole-exome sequencing, 3748 cases11,12; whole-genome sequencing, 1860 cases; Sanger sequencing, 650 cases) (eTable 2 in the Supplement). Variants in SPTLC1 were considered to be deleterious if they (I) were not pre-
sent in the 4647 controls from the Alzheimer Disease Sequencing Project; (2) had a frequency less than $3.3 \times 10^{-3}$ in human variant databases, including the 51,592 European and 8949 Finnish nonneurological individuals in gnomAD and the 77,301 samples in Kaviar database; and (3) were designated as damaging according to 4 of 5 prediction algorithms, were identified as stop gain or frameshift, or were identified as splice–site variants with a dbSNV score higher than 0.6. Gene burden testing of SPTLC1 was performed using publicly available control data (gnomAD and Kaviar databases) as implemented in the Test Rare Variants With Public Data (TRAPD) software package version 1.0.14 The statistical significance threshold was set at a 1-tailed $P \text{value} \leq 0.05$ for single-gene analysis and $2.5 \times 10^{-6}$ for genome-wide significance ($0.05/20,000$ genes).

**Cellular Mitochondrial Assays**

Variants were introduced into a plasmid containing the human SPTLC1 open reading frame (Origene) using the QuikChange II XL kit (Agilent), followed by subcloning into pLenti-C-Myc-DDK-P2A-Purolentiviral plasmid (Origene). Lentiviruses were produced with third-generation packaging plasmids (pMDLg/pRRE and pRSV-Rev; Addgene) and envelope plasmid (pMD2.G; Addgene). HEK293FT cells were transfected with wild-type or variant lentivirus transfer plasmid, and transduced cells stably expressing SPTLC1 were selected with extended growth in 0.5-μg/mL puromycin (Thermo Fisher Scientific). For the serine rescue experiment, a final concentration of 100-mM L-serine was added to the media for 48 hours. Mitochondria were imaged with MitoTracker Red CMXRs (Thermo Fisher Scientific) using a Cell Insights imager (Thermo Fisher Scientific). A minimum of 6 wells were quantified for each condition, and all assays were performed at least twice. Unpaired $t$ test with Welch correction or analysis of variance were used to calculate statistical significance.

**Sphingolipid Measurements**

Plasma sphingolipid and glucosylceramide measurements were performed at the Biomedical Genetics Clinical Laboratory, Seattle Children’s Hospital, Seattle, Washington, using high-performance liquid chromatography and tandem mass spectrometry.

**Results**

**Identification of De Novo Variants in SPTLC1 Associated With Juvenile ALS**

We performed whole-exome sequencing in 3 unrelated patients who had been diagnosed with juvenile ALS and their healthy parents (Figure 1; Figure 2A to C; Table). The analysis of their genetic data identified de novo variants in the SPTLC1 gene in each of the 3 patients that were absent in their parents (Figure 2E). Patients 1 and 2 carried the same heterozygous p.Ala20Ser variant in SPTLC1 caused by variation in adjacent nucleotides (chr9:94874844C>A and chr9:94874843G>T; human genome build hg19). Patient 3 carried a p.Ser331Tyr (chr9:94809543G>T) heterozygous variation in SPTLC1. Screening of the SPTLC1 gene in a cohort of 63 patients with juvenile ALS from Turkey who had undergone whole-exome sequencing identified a p.Leu39del (chr9:94874785_94874787del) heterozygous variant in patient 4 (Figure 2D). Parental DNA was not available, making it impossible to determine if the deletion had occurred spontaneously. These SPTLC1 variants were not present in controls or online databases of human variants (142,489 individuals). The p.Ser331Tyr and p.Leu39del amino acid changes have been previously implicated in neurological disease.16

**Serine and the Damaging Effects of the p.Ala20Ser Variant In Vitro**

Variants in SPTLC1 are a known cause of autosomal-dominant hereditary sensory and autonomic neuropathy, type 1A (HSAN1; OMIM, 162400).17,18 The protein encoded by SPTLC1 is an essential subunit of serine palmitoyltransferase (SPT), the enzyme that catalyzes the first and rate-limiting step in the de novo synthesis of sphingolipids.19 A characteristic feature of SPTLC1 variants associated with HSAN1 is a shift in substrate specificity of SPT to L-alanine and L-glycine, leading to the formation of an atypical class of deoxy sphingolipids.20 These neurotoxic metabolites accumulate within cells as they cannot be converted to complex sphingolipids nor degraded by the catabolic pathway.20

Based on this information, we used a photometric assay of SPT enzyme activity to explore the association of the de novo variants with protein function. We found that the p.Ala20Ser variant SPTLC1 complex had an altered L-alanine and glycine preference over the canonical L-serine compared with the wild-type SPTLC1 complex (Figure 3A; eFigure 1 in the Supplement). Differences were also observed using cell-based assays based on established HSAN1-mitochondrial phenotypes (Figure 3B and C; eFigure 1 in the Supplement).21 Mitochondrial size and intensity were defective to the same degree in cells expressing p.Ala20Ser and p.Cys133Trp. These defects were reversed to the wild-type phenotype on serine supplementation in the culture (Figure 3B and C; eFigure 1 in the Supplement).

**SPTLC1 Variants in Patients With Adult-Onset ALS**

Having established that variants in SPTLC1 are associated with juvenile ALS, we explored the role of variation in this gene in the pathogenesis of adult-onset ALS by evaluating the occurrence of SPTLC1 variants in a series of 6258 patients with adult-onset ALS. This screening identified 20 novel SPTLC1 variants in 23 patients with ALS (0.4%) that were rare or absent in healthy controls and were predicted to be damaging (eTable 3 and eFigures 2 and 3 in the Supplement). The typical clinical features of ALS were observed among these patients with adult-onset disease, and none of the patients reported sensory or autonomic involvement (eTable 4 in the Supplement). The intensity and number of motor neurons staining with SPTLC1 were diminished in autopsy tissue obtained from a patient with ALS carrying a p.Arg445Gln variant in SPTLC1 (eFigure 4 in the Supplement). Gene burden testing was not significant for SPTLC1 variants as a cause of adult-onset ALS (87 variants in population samples; uncorrected 1-sided Fisher test $P$ value using TRAPD software package $= 1.9 \times 10^{-4}$; not significant after correction for multiple testing of 20,000 genes).
We provide genetic, biochemical, and cellular data that variations in \( SPTLC1 \) are associated with juvenile ALS. First, we found 3 unrelated patients diagnosed with juvenile ALS who carried de novo variants in \( SPTLC1 \) and identified a fourth patient with juvenile ALS carrying another \( SPTLC1 \) variant for whom inheritance could not be determined. These variants were not present in our in-house control data set or in online databases of human variants, indicating they were rare variants in diverse populations. Two of the patients carried the same alanine to serine amino acid shift at position 20 of the protein, which arose from different nucleotide changes. Second, cell-based assays of SPT activity confirmed that the p.Ala20Ser and p.Cys133Trp \( SPTLC1 \) complex had increased preference for L-alanine and L-glycine over L-serine compared with the wild-type (WT) \( SPTLC1 \) complex. B and C, Mitochondria in HEK293 cells expressing WT, p.Ala20Ser, and p.Cys133Trp were assessed using MitoTracker on a high-content imager. Mitochondrial intensity and mitochondria size were smaller in cells expressing variant protein under standard culture conditions. Supplementation of 100 mM L-serine in the culture media for 48 hours rescued the mitochondrial abnormalities in the p.Ala20Ser and p.Cys133Trp lines.

**Discussion**

We provide genetic, biochemical, and cellular data that variations in \( SPTLC1 \) are associated with juvenile ALS. First, we found 3 unrelated patients diagnosed with juvenile ALS who carried de novo variants in \( SPTLC1 \) and identified a fourth patient with juvenile ALS carrying another \( SPTLC1 \) variant for whom inheritance could not be determined. These variants were not present in our in-house control data set or in online databases of human variants, indicating they were rare variants in diverse populations. Two of the patients carried the same alanine to serine amino acid shift at position 20 of the protein, which arose from different nucleotide changes. Second, cell-based assays of SPT activity confirmed that the p.Ala20Ser variant altered the encoded enzyme's function, leading to increased aberrant utilization of alanine and glycine as substrates. This biochemical pattern was consistent with a mechanism reported in patients with HSANI caused by \( SPTLC1 \) variants. Third, we used immunohistochemistry to demonstrate that \( SPTLC1 \) is abundantly expressed within the motor neurons of healthy spinal cord tissue.

Though labeled as HSANI, the phenotypes associated with variants in \( SPTLC1 \) are varied, with patients manifesting various combinations of sensory loss, autonomic dysfunction, and motor weakness. Indeed, there is a previous report of a de novo p.Ser331Tyr variant in \( SPTLC1 \) in a young French girl presenting with a similar phenotype to the patients in this article. Her clinical picture consisted of severe growth restriction, cognitive impairment, myotrophy, hyperreflexia, vocal cord paralysis, and respiratory failure, although this patient was not diagnosed as having juvenile ALS. More recently, retinal disease has been reported in patients carrying \( SPTLC1 \) variants. This clinical heterogeneity has been linked to the differing effects of each variant on \( SPTLC1 \) enzyme-substrate preference, and we observed similar differences in substrate utilization across the variants that we had studied at the enzymatic level (Figure 3A). Alternatively, the phenotypes associated with variants in HSANI may represent a continuum between sensory neuropathy and ALS. Future postmortem studies that deter-
mine the central nervous system pathology (eg, TAR DNA-binding protein 43, tau, β-amyloid deposition) underlying the motor neuron deficits and the cognitive impairment may resolve the nature of this overlap with other neurodegenerative diseases.

Perturbed sphingolipid metabolism underlies many neurological disorders, such as Niemann-Pick disease and Gauker disease, and may play a role in the pathogenesis of Alzheimer disease. Sphingolipid metabolism has also been implicated in motor neuron degeneration. For example, patients with partial deficiency of hexosaminidase A enzyme activity (also known as GM2 gangliosidosis, a form of sphingolipidosis) may have clinical manifestations mimicking ALS. The accumulation of ceramides and cholesterol esters also occurs within the spinal cords of patients with ALS and an SOD1 transgenic mouse model of ALS.

Owing to the poor prognosis observed among patients with juvenile ALS and work published by other groups, patient 2 was commenced on high-dose (10 g per day) oral serine supplementation on a compassionate basis. Her body weight increased during this off-label treatment, which was the first time she had gained weight in several years. The patient’s ceramide levels were within normal range and trending downwards, indicating that ceramide toxic effects, a theoretical possibility with serine treatment, were not present (Figure 5 and eTable 5 in the Supplement). We did not observe evidence of neurological improvement, although prolonged therapy would be required to detect such an effect.

Serine is a nonessential amino acid that is available as a low-cost nutritional supplement. A 10% serine-enriched diet was associated with a reduction in neurotoxic deoxy sphingolipid plasma levels both in transgenic mice expressing the p.Cys133Trp SPTLC1 variant and in human patients diagnosed with HSAN1. Furthermore, a safety trial involving 20 patients with adult-onset ALS demonstrated that high doses of oral serine are well tolerated and that this polar amino acid is actively transported across the blood-brain barrier. Nutritional supplementation has proven to be remarkably effective in other forms of ALS. Despite these supportive data, future clinical trials are needed to determine the effectiveness and safety profile of serine supplementation in patients with juvenile ALS owing to SPTLC1 variants.

Limitations
Our study had limitations. DNA was not available from the parents of patient 4, so it was not possible to determine whether or not the variation arose spontaneously. Nevertheless, the lack of a family history supports the possibility that this variant was de novo in origin; there is only a 3.1% chance that none of her 5 siblings would have inherited an autosomal-dominant variant from a transmitting parent. Our evidence also demonstrates that variants in SPTLC1 are not a common cause of adult-onset ALS. Overall, our data imply that the genetic causes of juvenile ALS and adult-onset ALS are distinct.

Conclusions
In conclusion, our data broaden the phenotype associated with variants in SPTLC1 to include juvenile ALS and implicate sphingolipid metabolism as a pathway in motor neuron disease. Our findings are relevant in light of the fact that nutritional supplementation with serine has been postulated to ameliorate the toxic effect of abnormal sphingolipid metabolites if instituted at an early stage in the disease. In such cases, abnormal plasma metabolites could be used as a marker of target engagement. This provides an early opportunity for future clinical trials to test the precision medicine approach in an otherwise fatal neurodegenerative disease.
Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis

Original Investigation Research

Khliefat, Tienari, Morrison, Al-Chalabi, Brown, Gotkine, Perlman, I. Glass, Scott, C. Shaw, Bajak, Landers, C. Giasson, B. Smith, Thompson, Soltis, Castellotti, Alba, Brady, Tiloca, Volti, Backova, Hupalo, Sukumaran, Pollard, Willerseon, Camu, Cooper-Knock, Drepper, Duncley, Eicher, Fratta, Geiger, Gibson, J. Glass, Hernandez, Janson, Kirby, Kowall, Lakssov, MacGowan, Maragakis, Murphy, Mylllykangas, Nalls, Oreil, Ostrow, Pahwa, Picketing-Brown, Pioro, Rollinson, Rothstein, Scholz, Sendtner, Sidle, Simmons, Van Deurlein, Zinnman, N. Smith, Landeck, Pietnikova, Keagle, Ma, McKenna, Yasek, Ares, D’Alfonso, Del Bo, Gagliardi, Corrado, Rouleau, Garcia-Rojo, Angeloccolo, Barberis, Berano, Cesana, Cassela, Conti, Cuccu, Dalla Bella, De Marco, Dubbioso, Flores, Fuda, Grassano, Introna, Laura, Mandrioli, Manero, Murr, ten Asbroek, Gkazi, Adeleye, Brice, King, Pugliatti, Riva, Zollino, Bowser.


Conflict of Interest Disclosures: Drs Tienari and Traynor hold the US, Canadian, and European patents on the testing and therapeutic intervention for the hexanucleotide repeat expansion in C9orf72. Dr Chiò serves on scientific advisory boards for Biogen Idec, Cytokinetics, Italianfarma, and Neuraltus. Dr Al-Chalabi reports consultancies for Biogen Idec, Cytokinetics Inc, OrphanPharma, Mitsubishi-Tanabe Pharma, and Mitsubishi-Tanabe Ltd. Dr Landers is a member of the scientific advisory board for Cerevel Therapeutics and a consultant and provides expert testimony for Perkins Coie. Dr Topp reports grants from UK Dementia Research Institute during the conduct of the study. Dr Dobson-Stone reports grants from National Health and Medical Research Council of Australia during the conduct of the study. Dr Kwok reports grants from National Health and Medical Research Council during the conduct of the study. Dr Tienari reports grants from Sigurd Julesius Foundation and Helsinki University Hospital during the conduct of the study. Dr Al-Chalabi reports grants from the UK Medical Research Council during the conduct of the study and has consulted for Biogen Idec, Onpharma, Amrylx, BrainStorm, Mitsubishi Tanabe Pharma, Cytokinetics, and Apellis outside the submitted work. Dr Landers reports grants from the ALS Association and National Institute of Neurological Disorders and Stroke during the conduct of the study as well as personal fees from Cerevel Therapeutics and Perkins Coie outside the submitted work. Dr Chio reports personal fees from Biogen Scientific and Cytokinetics Science Foundation, and Merck, US Centers for Disease Control and Prevention, US Veterans Administration, and Microsoft Research outside the submitted work; and is on the editorial board of JAMA Neurology, Journal of Neurology, Neurosurgery, and Psychiatry; Neurobiology of Aging; and Brain. Dr Stone is an employee of Cerevel Therapeutics. Dr Pollard reports grants from the National Institutes of Health during the conduct of the study. Dr Baloh is employed by Roche Pharmaceuticals. Dr Eicher is an employee of Merck and GlaxoSmithKline. Dr Faghri reports personal fees from National Institutes of Health outside the submitted work. Dr Feldman reports grants from the National Institutes of Health, US Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, Novo Nordisk Foundation, and JDRF and personal fees from Novartis outside the submitted work. Dr Geiger reports personal fees from the National Institutes of Health during the conduct of the study. Dr Harms reports grants from Biogen, ALS Association, and Project ALS during the conduct of the study as well as personal fees from Invivio and VariantBio outside the submitted work. Dr Heiman-Patterson reports grants from Mitsubishi Tanabe America and personal fees from Samus, Cytokinetics, IIT, and Orion outside the submitted work. Dr Leitner reports grants from the National Institutes of Health. Dr Orell reports grants from Motor Neurone Disease Association during the conduct of the study. Dr Scholz reports grants from Target ALS Foundation during the conduct of the study and grants from ALS Association outside the submitted work. Dr Rothstein reports grants from Calico Therapeutics and GlaxoSmithKline; personal fees from Expansion Therapeutics; and nonfinancial support from Ionis Pharmaceuticals outside the submitted work. Dr Scholtz reports serving on editorial boards of the Journal of Parkinson’s Disease, Frontiers in Neurology, Frontiers in Neuroscience, Frontiers in Psychiatry, and JAMA Neurology. Dr Simmons reports personal fees from Biogen, Amrylx, and Alexion and grants from MT Pharma outside the submitted work. Dr Troncoso reports grants from the National Institutes of Health Alzheimer’s Disease Research Center during the conduct of the study. Dr Van Damme reports grants from CSL Behring and fees from Biogen, Alexion Pharmaceuticals, Ferrer, QuAlis, and Argenx paid to his institution outside the submitted work. Dr Baas reports personal fees from ComplementPharma outside the submitted work. Dr Hardiman reports grants from Science Foundation Ireland during the conduct of the study as well as personal fees from Taylor & Francis outside the submitted work. Dr Wielink reports grants from Biogen outside the submitted work. Dr van den Berg reports grants from Netherlands ALS Foundation during the conduct of the study. Dr Turner reports grants from Motor Neurone Disease Association as well as personal fees from Orphazyme, Oxford University Press, and BMA Journals outside the submitted work. Dr Taroni reports grants from Italian Ministry of Health during the conduct of the study as well as grants from Italian Ministry of Health and Fondazione Regionale per la Ricerca Biomedica (FRBB) outside the submitted work. Dr Corbo reports personal fees from Biogen outside the submitted work. Dr Filippi reports personal fees from Almirion, Alexion, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva; grants from Biogen, Merck, Roche, and Teva outside the submitted work; and is an Editor-in-Chief of the Journal of Neurology and Associate Editor of Human Brain Mapping. Dr Ligouri reports personal fees from ARGENX BV outside the submitted work. Dr Mandrioli reports nonfinancial support from Pfizer outside the submitted work. Dr Brice reports grants from Institut de France Prix de Recherche Allianz 2018, ANR-EPIC, France Parkinson + FRC, and APHP Extraction d’ADN à partir de prélèvements sanguins, conservation des échantillons d’ADN extraits et distributions d’aliquots d’ADN pour analyse outside the submitted work. Dr Bisogno reports personal fees from Alynlam outside the submitted work. Dr Tedeschi reports grants from Roche, Biogen, Allergan, Merck, Novartis, and Lilly outside the submitted work. Dr Bowser reports personal fees from Iron Horse Diagnostics outside the submitted work. No other disclosures were reported.

Support/Funding: This work was supported in part by the Intramural Research Programs of the National Institute on Aging (grant Z01-AG000949-02) and National Institute of Neurological Disorders and Stroke (grant 2IA-N50315). The work was also funded by the Packard Foundation Center for ALS Research at Stanford University, the ALS Association (grant 20-25-S08), the Muscular Dystrophy Association, the Italian Ministry of Health (grant RF-2016-02362405), the Italian Ministry of Education, University and Research (Progetto di Ricerca di Rilevante Interesse Nazionale [PRIN], grant 2017SN5W5M8), the Joint Programme-Neurodegenerative Disease Research Initiative (JPN-D Brain-Mend projects) granted by Italian Ministry of Education, University and Research, and by the European Community’s Health Seventh Framework Programme (FP7/2007–2013; grant agreements 259867 and 278681), by the National Institute of Neurological Disorders and Stroke (grants R33 NS097261, R01NS073873, and R56NS073873), and by the Collaborative Health Initiative Research Program. This study was performed under the Department of Excellence grant of the Italian Ministry of Education, University and Research to the ‘Rita Levi Montalcini’ Department of Neuroscience, University of Torino, Italy. Additional funding was also provided by the Motor Neurone Disease Association (MND), the Medical Research Council, the Medical Research Foundation (MRF), the Van Geest Foundation, the Psychiatry Research Trust of the Institute of Psychiatry, Guy’s and St. Thomas’ Charity and the Noreen Murray Foundation, the Sigrid Julesius Foundation, the UK Dementia Research Institute, the National Health and Medical Research Council of Australia (grants 1095215 and 1092023), and through the following funding organisation under the aegis of JPN-D: UK Medical Research Council (grants MR/L051529/1 and MR/R024804/1). This work was supported by the Canadian Consortium on Neurodegeneration in Aging, UK Dementia Research Institute, which is funded by the Medical Research Council, Alzheimer’s Society, and the UK Alzheimer’s Research UK. Dr Al-Chalabi is supported by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre. Dr P. Shaw is supported as an NIHR Senior Investigator and by the Sheffield NIHR Biomedical Research Centre. Dr Dobson-Stone is supported by ...
the Australian National Health and Medical Research Council (NHMRC) Boosting Dementia Research Leadership Fellowships (U11B2223) and by the University of Sydney. Dr. Kwok is supported by NHMRC Dementia Research Team Grant 1095127. The Alzheimer’s Disease Sequencing Project (ADSP) is comprised of 2 Alzheimer’s Disease (AD) genetics consortia and 3 National Human Genome Research Institute (NHGRI)-funded Large-Scale Sequencing and Analysis Centers (LSAC). The AD genetic consortia are the Alzheimer’s Disease Genetics Consortium (ADGC) funded by National Institute on Aging grant U01 AG032984, and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) funded by National Institute on Aging (RO1 AG033193), the National Heart, Lung, and Blood Institute, other National Institutes of Health institutes, and other foreign governmental and nongovernmental organizations. The Discovery Phase analysis of sequence data is supported through U1FAGO47133 to the following: Austrian Stroke Prevention Study, and Haines, U01AGO49505 to Dr. Seshadri; U01AGO49506 to Dr. Boerwinkle; U01AGO49507 to Dr. Wijsman; and U01AGO49508 to Dr. Goate. The Discovery Extension Phase analysis is supported through U101AG05241 to Dr. Goate, U101AG05242 to Dr. Pericak-Vance, and U01 AG052409 to Dr. Seshadri and Fornage. Data generation and harmonization in the Follow-up Phases is supported by U54 AG052427 (to Drs. Schellenberg and Wang). The ADGC cohorts include Adult Changes in Thought (ACT), the Alzheimer’s Disease Centers (ADC), the Chicago Heart and Aging Project (CHAP), the Memory and Aging Project (MAP), Mayo Clinic, Mayo Parkinson’s Disease controls, University of Miami, the Multi-Institutional Research in Alzheimer’s Genetic Epidemiology Study (MIRAGE), the National Cell Aging Project (CHAP), the Religious Orders Study (RO5), the Texas Alzheimer’s Research and Care Consortium (TARC), Vanderbilt University/Case Western Reserve University (VAN/ CWRU), the Washington Heights-Inwood Columbia Aging Project (WHICAP), and the Washington University Sequencing Project (WUSP), the Columbia University Hispanic–Estudio Familiar de Influencia Genetica de Alzheimer (EFFGA), the University of Toronto, and Genetic Differences (GD). The CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute infrastructure grant HL105756 (Padyuk, RCL2L1Q2419 (Boerwinkle), and the Neurology Working Group is supported by the National Institute on Aging RO1 grant AG033193. The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study (ASPS), ASPS-Family study, and the Progressive Dementia Registry-Austria (ASPS/PRODEM-Aus), the Attherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is funded by the Austrian Science Fund (FWF) grants P20545-P05 and P13180 and the Medical University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project 1904, the EU Joint Programme—Neurodegenerative Disease Research (JPNDR) in frame of the BRIDGE project (Austria, Ministry of Science) and by the Medical University of Graz and the Steiermärkische Krankenanstalten Gesellschaft. PRODEM—Austria is supported by the Austrian Alzheimer Promotion agency (FYG) (project BZT46ZD) and the Austrian National Bank (project Fund 154S3). ARIC research is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN26820100003C, HHSN26820100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01HL096812, 2U01HL096814, 2U01HL096992, 2U01HL096990, 2U01HL096917 from the National Institutes of Health, and with previous brain magnetic resonance imaging examinations funded by RO1-HL70825 from the National Heart, Lung, and Blood Institute. CHS research was supported by contracts HHSN268201200036C, HHSN268201200007C, N01HC55222, N01HC55279, N01HC55280, N01HC55281, N01HC55285, N01HC55278, and grants U01HL082925 and U01HL130119 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG023629. RO1AG059197 is from the National Institute on Aging. FHS research is supported by National Heart, Lung, and Blood Institute contracts N01-NC-25195 and HHSN2682015000011. This study was also supported by additional grants from the National Institute on Aging (ROIs AG54076, AG049607, and AG033040) and National Institute of Neurological Disorders and Stroke (RO1 NS071950). The ERF study as part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant 018947 (LSHC-CT-2006-18947) and also received funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) and grant agreement HEALTH-F4-2007-202413 by the European Commission under the programme “Quality of Life and Management of the Living Resources” of 5th Framework Programme (No. GQ2-CT-2002-01254). High-throughput analysis of the ERF data was supported by a joint grant from the Netherlands Organisation for Scientific Research and the Russian Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIJE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the municipality of Rotterdam. Genetica-BV is also supported by the Netherlands Organisation of Scientific Research (NWO) Investments (175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015, RIDEC), and the Netherlands Genomics Initiative (NGI). Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA; project 050-060-810). All studies are grateful to their participants, family, and staff. The content of these articles is solely the content of these articles is solely the content of these articles is solely the content of these articles is solely the content of these articles is solely the content of these articles is solely the

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University or the US Department of Defense.

Additional Contributions: We thank patients 1 and 4 and the parents of patient 3 for granting us permission to publish information about them. We thank the patients and their families for their participation in our research. We also thank Kirsty McWalser, MS, and other staff of GeneDx, Gaithersburg, Maryland, for their assistance. This study used DNA samples, genotypic data, and clinical data from the National Institute of Neurological Disorders and Stroke Repository at Coriell, the New York Brain Bank, The Taub Institute, Columbia University, Department of Veterans Affairs Biorepository Brain Bank (grant BX02466), the Baltimore Longitudinal Study of Aging, the Johns Hopkins University Alzheimer’s Disease Research Center (National Institutes of Health grant P50 AG030315), the National Institute of Child Health and Human Development Brain and...
SOD-1 sporadic ALS associated with a novel hurn mutation. Genotype-phenotype analysis in 2,405 patients
5

References


